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Abstract
The inv(16) acute myeloid leukemia-associated CBFβ-MYH11 fusion is proposed to block normal myeloid
differentiation, but whether this subtype of leukemia cells is poised for a unique cell lineage remains unclear. Here, we
surveyed the functional consequences of CBFβ-MYH11 in primary inv(16) patient blasts, upon expression during
hematopoietic differentiation in vitro and upon knockdown in cell lines by multi-omics proﬁling. Our results reveal that
primary inv(16) AML cells share common transcriptomic signatures and epigenetic determiners with megakaryocytes
and erythrocytes. Using in vitro differentiation systems, we reveal that CBFβ-MYH11 knockdown interferes with normal
megakaryocyte maturation. Two pivotal regulators, GATA2 and KLF1, are identiﬁed to complementally occupy RUNX1-
binding sites upon fusion protein knockdown, and overexpression of GATA2 partly induces a gene program involved
in megakaryocyte-directed differentiation. Together, our ﬁndings suggest that in inv(16) leukemia, the CBFβ-MYH11
fusion inhibits primed megakaryopoiesis by attenuating expression of GATA2/KLF1 and interfering with a balanced
transcriptional program involving these two factors.
Introduction
Core-binding transcription factors (CBFs) have been
proposed to shape both stem cell self-renewal and dif-
ferentiation, and their dysfunction could potentially lead
to cancer pathogenesis1. The CBFs are heterodimeric
complexes composed of two distinct subunits, alpha and
beta2. The CBF α-subunit is encoded by the RUNX family
(usually RUNX1/AML1 in the hematopoietic cells) and
directly contacts the DNA sequence, whereas the non-
DNA-binding CBF β-subunit is thought to facilitate sta-
bilizing the DNA afﬁnity of the CBF complex. CBFs are
often mutated in acute myeloid leukemia (AML), for
example, in t(8;21) AMLs, characterized by expression of
the AML1-ETO fusion gene, or inv(16) AMLs, delineated
by the presence of the CBFβ-MYH11 (CM) event3. CBFβ-
MYH11 encodes a fusion protein between CBFβ and
smooth muscle myosin heavy chain (SMMHC/MYH11),
and is associated with AML FAB subtype M4Eo
accounting for around 6% of AML cases4–6. However, our
understanding of its roles in leukemogenesis remains
incomplete.
Expression of CBFβ-MYH11 is able to disrupt normal
myeloid differentiation, predispose for AML initiation,
and cause full leukemia transformation upon the
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acquisition of additional genetic changes7,8. A recent
study revealed that CBFβ-MYH11 maintains inv(16) leu-
kemia by obstructing RUNX1-mediated repression of
MYC expression, which is featured by the replacement of
SWI/SNF for PRC1 at MYC distal enhancers9. However,
at which differentiation stage CBFβ-MYH11 blocks
myeloid differentiation is still unclear. Mutational analysis
of FACS-puriﬁed hematopoietic stem cells (HSCs) as
compared to leukemia cells conﬁrmed the presence of
CBFβ-MYH11 in HSCs, suggesting that the fusion event is
involved in setting up a preleukemic cell state10. Further
pursuing which differentiation pathway exactly is targeted
by the oncoprotein would be needed.
At the molecular level, CBFβ-MYH11 in a complex with
RUNX1 acts as a transcriptional regulator, which can
depending on local genomic context, activate and repress
genes involved in self-renewal, differentiation, and ribo-
somal biogenesis6,11,12. Our previous ﬁndings have shown
that a variety of cell surface markers increase in expres-
sion levels upon knockdown of CBFβ-MYH11 in the inv
(16) cells, including those for the monocytic and mega-
karyocytic lineages11. In addition, mouse studies revealed
that expression of the CBFβ-MYH11 protein causes
abnormal erythropoiesis and gives rise to preleukemic
pre-megakaryocyte/erythrocyte progenitors8,13. Overall,
these results potentially implicate a role of the CBFβ-
MYH11 fusion in skewing cell differentiation orientation.
To investigate whether CBFβ-MYH11 speciﬁcally blocks
megakaryocyte/erythrocyte differentiation in the context
of human hematopoiesis, and further probe its molecular
mechanisms, we analyzed multiple transcriptomic and
epigenomic proﬁles of inv(16) AMLs, several normal
hematopoietic cell types and in vitro single-oncogene
models. Our ﬁndings reveal a clustering of inv(16) AMLs
towards megakaryocytes and erythrocytes based on DNA
accessibility and H3K27ac-based super-enhancer (SE)
proﬁles. Further molecular exploration indicates that
CBFβ-MYH11 seems to be involved in interfering with
normal differentiation through transcription deregulation
and occupancy replacement of the transcription factors
GATA2 and KLF1. Together, these results suggest that
controlled expression of KLF1 and GATA2 expression is
essential for inv(16) AML development.
Materials and methods
Human cells collection and sequencing
Leukemic samples were either obtained from bone
marrow or peripheral blood for subsequent processing.
Patients cells and cell lines were processed through
multiple steps as previously reported11, and then sub-
jected to high-throughput transcriptome and chromatin
immunoprecipitation (ChIP) sequencing for histone
marks, CBFβ-MYH11 fusion, RUNX1, and GATA2 as
described in the Supplementary Information.
Assays
Cell culture, ﬂow cytometry, cytospin, differentiation of
iPSCs towards the granulocytic lineage, nuclear extraction
preparation, pulldown, and mass spectrometry analysis
were performed as detailed in the Supplementary
Information.
Bioinformatics analysis
Peak calling
After read mapping to the hg19 reference genome using
BWA14 and removal of PCR duplicates by Picard Mark-
Duplicates option (http://broadinstitute.github.io/picard/),
peak calling of CBFβ-MYH11 fusion, RUNX1, and
GATA2 ChIP-seq was conducted using MACS1.3.315 at a
p-value cutoff of 10−6. For DNA accessibility and H3K27ac
data in inv(16) patients, the detailed analyses procedure
was described as before16.
Super-enhancer identiﬁcation
All H3K27ac peaks identiﬁed were ﬁltered to exclude
regions within ±2.0 kb around transcription start sites
(TSSs), and then used as input for the ROSE algorithm17
to predict SEs.
Tag counting
Read counts for each putative region were enumerated
and then normalized to RPKM (reads per kilobase of gene
length per million reads) for visualization in heat maps or
boxplots. For each base pair in the genome, the number of
overlapping sequence reads was determined, averaged
over a 10 bp window, and visualized in the UCSC genome
browser (http://genome.ucsc.edu).
Motif analysis
Motif discovery was performed using GimmeMotifs18
with a threshold score of 0.9 (on a scale from 0 to 1).
Expression analysis
RNA-seq reads were uniquely mapped to the hg19
reference genome using STAR19, and subsequently nor-
malized to RPKM values for all RefSeq genes using tag
counting scripts. Gene-level count matrix was used as
input for DESeq2 package20 to distinguish differentially
expressed genes between any two groups. Signiﬁcant
genes were determined by a fold change cutoff of 1.5 and
adjusted p-value of 0.01.
Results
CBFβ-MYH11 expressing cells harbor transcriptional
characteristics of megakaryocytic and erythroid cells
To examine the transcriptional differences between inv
(16) AML patients expressing CBFβ-MYH11 and normal
hematopoietic cell types, we used RNA-seq and compared
global gene expression levels between AML blasts and
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normal CD34+ progenitor cells (CD34), megakaryocytes
(Mega), erythrocytes (Ery), and monocytes (Mono).
Unsupervised principal component analysis (PCA)
revealed that inv(16) AMLs displayed different tran-
scriptomic landscapes as compared to normal lineages
(Supplementary Figure 1A). The main source of variability
(PC1) was the difference between Mega/Ery and CD34/
inv(16) cells (Fig. 1a), with the top contributing genes in
PC1 mainly involved in immune response terms. In
contrast, the second component (PC2) showed signiﬁcant
similarity between inv(16) and Mega/Ery, and was enri-
ched in cell differentiation related terms (Fig. 1a). The
transcriptional difference between inv(16) leukemic blasts
and normal cells was revealed by PC3, which terms
associated with leukocyte migration and activation. Each
pairwise comparison between individual normal cell type
and inv(16) blasts revealed more than 2000 differentially
expressed genes (Fig. 1b, Supplementary Table 1). Toge-
ther, these results suggest that inv(16) AMLs carry unique
gene expression signatures (PC3), but also signatures that
resemble CD34+ progenitor cells (PC1) or mature cells
such as megakaryocytes (PC2).
Next, all differentially expressed genes were clustered
into eight groups by the k-means clustering method
(Supplementary Figure 1B, C). Besides cell-type-speciﬁc
clusters (C1, C4, C6, and C8), we again found that inv(16)
blasts shared gene signatures with normal cell types. For
instance, the C2 cluster revealed similar expression pat-
terns between inv(16) and CD34+ progenitors, while the
inv(16) genes expressed in C3 resembled more closely a
Mono signature. Furthermore, the primary inv(16) blasts
shared a subset of gene signatures with Mega/Ery as
shown in the C5 and C7 cluster (Fig. 1c), although these
genes also displayed similar expression levels in CD34 or
Mono. These ﬁndings indicate that inv(16) blasts main-
tained certain transcriptional signatures from progenitors,
but also already obtained characteristics of mature cells.
Different hematopoietic cell types can be identiﬁed by
examining expression of cluster of differentiation (CD)
markers. Here, we identiﬁed 236 CD markers differen-
tially expressed between inv(16) and normal cells. Our
previous studies showed altered transcriptional activity of
CD markers upon transient knockdown of CBFβ-MYH11
in ME-1 cells11. To examine whether the 236 differentially
expressed CD markers from this study might be directly
regulated by CBFβ-MYH11, we compared the two data-
sets. More than half of CBFβ-MYH11-dependent CD
markers (84/130) were also differentially expressed in the
comparison of normal cell types versus inv(16) AMLs
(Fig. 1d), suggesting putative regulation by CBFβ-MYH11.
Among these, myeloid stem cell markers like CD34 and
CD133 displayed signiﬁcantly higher expression levels in
inv(16) AML than other mature cells (Fig. 1e). However,
some markers of mature cells like CD64 and CD71 were
also expressed in inv(16) AML, suggesting inv(16) cells
might already be partly differentiated.
To extend this ﬁnding we examined several other
marker genes involved in hematopoiesis including GFI1B,
RUNX1, and GATA2 (Supplementary Figure 2A). It has
been shown that expression of GFI1B is key to mega-
karyocyte and platelet development21. Moreover, CBFβ-
MYH11 binds a putative downstream regulatory element
of GFI1B gene11 (Supplementary Figure 2B). We con-
ﬁrmed the highest transcriptional level of GFI1B in Ery/
Mega, but also found that the inv(16) blasts expressed
higher levels of GFI1B as compared to Mono, and similar
to CD34 progenitors (Supplementary Figure 2A). Toge-
ther, our results suggest that expression of CBFβ-MYH11
leads to impaired differentiation in part through dereg-
ulation of genes involved in maturation of megakaryocytic
cells.
Epigenomic clustering of inv(16) cells, megakaryocytes,
and erythroblasts
To further investigate whether cells blocked by CBFβ-
MYH11 are poised for a certain lineage we compared
epigenetic landscapes. For this, we generated DNaseI-seq
and H3K27ac ChIP-seq proﬁles16 in inv(16) AML cells
and compared those to proﬁles created in Mega, Ery, and
Mono. In addition, we downloaded public ATAC-seq
data22, which showed high consistency with DNaseI-seq
(Supplementary Figure 3A), from several progenitor cell
types including HSC, common myeloid progenitor,
granulocyte–macrophage progenitor cell, and
megakaryocyte-erythroid progenitor cell, to assess the
similarity with inv(16) AMLs in open chromatin patterns.
Principal component analysis (PCA), the t-distributed
stochastic neighbor embedding (t-SNE) and hierarchical
clustering results based on DNA accessibility showed
robust classiﬁcation of cell types and differentiation tra-
jectory (Fig. 2a, b). Interestingly, the inv(16) AML cells
displayed most similarity in open chromatin signatures
and hence closer relationships with Mega and Ery cells
(Fig. 2b, Supplementary Figure 3B).
Given that SEs are able to precisely capture cell iden-
tity23, we delved into genome-wide SEs landscapes using
H3K27ac proﬁling. To integrate progenitor cells in our SE
analysis, we downloaded H3K27ac data of CD34+ cells
from NIH Roadmap Epigenomics24. The proﬁles of CD34,
inv(16), Mega, Ery, and Mono demonstrated high-quality
H3K27ac-binding patterns and cell-type-speciﬁc SEs
proﬁles, for example at the GATA2, PF4, and IRF8 loci
(Fig. 2c, Supplementary Table 2). PCA analysis of
H3K27ac signal at SEs conﬁrmed these ﬁndings and
showed that principal component 1 could clearly separate
Mono from CD34, inv(16), Mega, and Ery, and also reveal
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Fig. 1 The deregulated gene expression programs of primary inv(16) AML blasts compared to four normal cell types. a The transcriptional
relationship based on RNA-seq among cell types revealed by principal component analysis. The ﬁve cell types are CD34+ progenitor cell (CD34),
primary inv(16) AML cell (inv(16)), erythrocyte (Ery), megakaryocyte (Mega), and monocyte (Mono). b Pairwise gene expression comparison between
primary inv(16) cells with other cell types. c Two example clusters after deﬁning distinct expression patterns by k-means clustering among ﬁve cell
types (see also Supplementary Figure 1B). The raw p-value in functional enrichment is adjusted by the Benjamini–Hochberg procedure. d Overlap of
differentially expressed cell markers between our previous study (Mandoli et al., 2014) and the present study. NM_cells: normal cell types (CD34,
Mega, Ery, and Mono), CM_KD: CBFβ-MYH11-knockdown cells, CTR: control cells. e Transcriptional changes for several cell-type-speciﬁc markers.
Labels in the parentheses indicate which cluster from Supplementary Figure 1B this gene is from
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relatively closer distance between inv(16) and Mega/Ery
(Fig. 2d, Supplementary Figure 3C). Pearson clustering of
SEs again uncovered preferential grouping of inv(16) cells
with CD34, Mega, and Ery, while Mono SEs formed an
individual cluster (Fig. 2e). Overall, these results suggest
that consistent with our RNA-seq ﬁndings, inv(16) AML
cells might carry a speciﬁc epigenetic state with high
similarity to Mega/Ery cells, and represent cells that are
putatively blocked along the Mega/Ery differentiation
pathway.
CBFβ-MYH11 single oncogene expression blocks
megakaryocyte/erythrocyte differentiation
A major limitation when analyzing inv(16) cell lines and
primary inv(16) AML blasts is that they harbor many
additional mutations. To exclude the disturbance of other
genetic lesions, we utilized an in vitro iPSC-based
hematopoietic differentiation system in which the
expression of a single oncogene can be induced with
doxycycline (dox), as successfully conducted in our pre-
vious study25. The established system contains dox-
Fig. 2 Primary inv(16) cells are epigenetically more similar to megakaryocytes and erythrocytes. a PCA and t-SNE analysis of DNA accessibility
data display a clear separation along cell differentiation trajectories. Normal cell types include hematopoietic stem cell (HSC), common myeloid
progenitor (CMP), granulocyte-macrophage progenitor cell (GMP), megakaryocyte-erythroid progenitor cell (MEP), erythrocyte (Ery), megakaryocyte
(Mega), and monocyte (Mono). inv(16): primary inv(16) AML cell. b Hierarchical clustering of the top 5000 variable DNA accessibility sites. Numbers on
the branch indicate bootstrap support scores over 1000 samplings. c Variable super-enhancer landscapes (H3K27ac ChIP-seq) in the GATA2, PF4/PPBP
and IRF8 loci. SE: super-enhancer. Average H3K27ac density of three CD34 cells and nine monocytes were calculated for better visualization. d, e
Principal component 1 (PC1) and clustering plots of cell type relationship based on H3K27ac signal in super-enhancers
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inducible CBFβ-MYH11 (Fig. 3a, b) and we expressed the
oncoprotein during differentiation towards the granulo-
cytic, monocytic, and megakaryocyte lineage (Fig. 3c),
allowing the investigation of the effects of CBFβ-MYH11
in the absence of additional leukemia driver mutations.
Flow cytometry analysis of four independent experiments
using iPS cells in which CBFβ-MYH11 expression was
induced revealed a remarkable reduction in CD41a,
CD42b, and CD235a positive cells during megakaryocyte/
erythrocyte differentiation as compared to iPS cells not
expressing CBFβ-MYH11 (Fig. 3d, Supplementary Figure
4). In contrast, no signiﬁcant effects were observed during
monocyte and granulocyte/neutrophil differentiation.
Together, these results reﬂect that CBFβ-MYH11 has a
dominant effect on blocking Mega/Ery differentiation,
and suggest inv(16) cells might correspond to cells that
are arrested in a progenitor stage of this lineage.
CBFβ-MYH11 knockdown affects cell proliferation
To further explore the detailed functional pathways
induced by CBFβ-MYH11 alone, we generated a stable dox-
inducible CBFβ-MYH11-knockdown (KD) cell line based
on the inv(16) cell line ME-126) (Fig. 4a), and further
examined genome-wide changes in the transcriptome as
well as the acetylome. Previously, CBFβ-MYH11 transduc-
tion of CD34+ cells was shown to enhance proliferation27.
In line with these results, knockdown of CBFβ-MYH11 in
ME-1 cells affected proliferation, with more cells in the G1
phase and more cell adherence11, while a slight reduction in
cell viability was observed (Fig. 4b, c). The latter ﬁnding was
also supported by an increased number of cells in the sub-
G1 cell phase, which is indicative of apoptotic or necrotic
cell death (Fig. 4c, Supplementary Figure 5). To provide
further evidence for the differentiation stage of the cells
after CBFβ-MYH11 knockdown, we performed cell
Fig. 3 The CBFβ-MYH11 oncogene blocks cell differentiation towards megakaryocyte/erythrocyte lineages. a Western blots of the CBFβ-
MYH11 oncoprotein in the inv(16) AML ME-1 cell line and in the iPSC system before and after dox addition. Arrows point to the endogenous CBFβ
and inducible expressed CBFβ-MYH11 protein. Asterisks represent aspeciﬁc binding of the antibody. Molecular weight markers in kilodaltons are
listed on the left. b Expression levels of the CBFβ-MYH11 oncogene in ME-1 cells and in iPSC without (CTR) or after dox induction of CBFβ-MYH11. c
The methodology for iPSC differentiation towards neutrophil, macrophage, and megakaryocyte lineages. d The percentage of cells showing speciﬁc
myeloid markers after differentiation following the protocols in c. The mean and standard deviation of cell fractions from four independent
differentiation experiments are shown. A p-value of <0.05 was considered statistically signiﬁcant by Wilcoxon signed-rank test: *p < 0.05
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Fig. 4 (See legend on next page.)
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counting and morphology analysis. Delayed expansion for
CBFβ-MYH11 KD cells was observed as compared to
control after 3 days of culture (Fig. 4d). Furthermore, the
morphology of KD cells by cytospin showed the presence of
polyploid cells with increased size and decreased
nuclear–cytoplasmic ratio that morphologically resemble
megakaryocytes (Fig. 4e), again suggesting that these cells
after CBFβ-MYH11 knockdown become more mega-
karyotic. Transcriptome analysis between control and
CBFβ-MYH11-knockdown cells at day 5 corroborated the
effect on cell cycle, with genes involved in controlling DNA
replication and cell cycle pathways increased in expression
level (Fig. 4f). Together these results suggest that CBFβ-
MYH11 knockdown might trigger the onset of differentia-
tion and cell cycle arrest28.
Given that altered transcriptional levels are a reﬂection
of epigenetic changes, we performed H3K27ac ChIP-seq
(positively correlated with gene expression) on control
and CBFβ-MYH11 knockdown cells, and inspected dif-
ferential H3K27ac peaks (>100 tags and two-fold differ-
ence). A total of 2309 differential regions were identiﬁed,
around 16.2% of them were covered by SEs from inv(16)
AML patients. The genes associated with regions showing
increased acetylation after knockdown were functionally
related to megakaryocyte differentiation and platelet for-
mation (Fig. 4g, h), while genes assigned by loci going
down in acetylation were involved in leukocyte physiol-
ogy. Motif analysis in the two types of peaks revealed
enrichment for MEF2A and ERG/FLI1 motifs in regions
attenuated in H3K27ac signal (Fig. 4h, right). In contrast,
(see ﬁgure on previous page)
Fig. 4 Cell cycle deregulation induced by CBFβ-MYH11 fusion. a RT-qPCR analysis of CBFβ-MYH11 and CBFβ in ME-1 cells before and after CBFβ-
MYH11 knockdown (KD). Data are normalized to GAPDH expression level. b Cell viability in response to CBFβ-MYH11 knockdown. c FACS analysis
showing the percentage of cells in four cell cycle phases after CBFβ-MYH11 knockdown. d Cumulative cell counts in culture of ME-1 cells before and
after CBFβ-MYH11 knockdown. e Cell morphology of ME-1 cells before and after CBFβ-MYH11 knockdown. In the KD group, we found more
polyploid cells (49.4% compared to 17.3% in control) with increased size and decreased nuclear–cytoplasmic ratio. f Log2 fold change (LFC) of ME-1
CBFβ-MYH11 knockdown vs ME-1 control cells for a replicate RNA-seq experiment. Involved pathways of differentially expressed genes between
control and CBFβ-MYH11-knockdown cells are indicated. g Differential H3K27ac enrichment before (CTR) and after (KD) CBFβ-MYH11 knockdown. h
Functional annotation of genes and enriched motifs associated with differential H3K27ac peaks
Fig. 5 Identiﬁcation of interactors affected by the CBFβ-MYH11 fusion. a Western blot analysis of a DNA pull-down experiment in ME-1 cells
using CBFβ and RUNX1 antibodies. b Scatterplot showing the CBFβ-MYH11 interactome. Proteins interacting with a RUNX1 motif containing oligo
before or after CBFβ-MYH11 knockdown are plotted by their SILAC-ratios in the forward (x-axis) and reverse (y-axis) SILAC experiment. Speciﬁc
interactors with the RUNX1 motif containing oligo that bind upon CBFβ-MYH11 protein depletion lie close to the diagonal in the upper left quadrant.
Interactors for which binding is CBFβ-MYH11 dependent are in the lower right quadrant
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H3K27ac-increased regions were signiﬁcantly occupied by
SP1 and E2F motifs, again suggesting deregulation of the
DNA replication machinery29.
CBFβ-MYH11 knockdown increases GATA2/KLF1
occupancy at RUNX1-binding sites
Given that we observed signiﬁcant changes in tran-
scription and H3K27ac occupancy after CBFβ-MYH11
knockdown, we set out to further excavate its regulatory
mechanisms. As CBFβ-MYH11 binds the RUNX1 protein,
it potentially interferes with the normal RUNX1-regulated
gene program. To investigate the proteins which might be
implicated in altering the transcriptional program, we
performed DNA pull-down experiments using a speciﬁc
nucleotide sequence bound by CBFβ-MYH11 that con-
tains the RUNX1 core consensus motif TGTGGT
(RUNX1 oligo), in control and CBFβ-MYH11-knockdown
ME-1 cells (Fig. 4a). The principle is to use this DNA
probe to pull-down not only direct interactors with this
sequence, but also all associated proteins, which are then
identiﬁed by mass spectrometry. When performing the
pull-down experiment using cells in which CBFβ-MYH11
is expressed and the same cells in which CBFβ-MYH11
has been knocked down, you can, based on the ratio of
protein binding, determine which proteins are binding to
the RUNX1-motif oligo in a CBFβ-MYH11 dependent
fashion.
We could show that the oligonucleotide with the
RUNX1 motif efﬁciently pulled down CBFβ-MYH11 as
well as RUNX1 and CBFβ from an ME-1 cell lysate (Fig.
5a), whereas signiﬁcantly attenuated afﬁnity for CBFβ-
MYH11 was observed when the knockdown cell lysate
was used. Importantly, knockdown of CBFβ-MYH11 did
not affect RUNX1 and wild-type CBFβ occupancy, sug-
gesting changes in protein-binding proﬁles are likely due
to the absence of CBFβ-MYH11.
To decipher the interactome of the CBFβ-MYH11
complex at RUNX1-binding sites, we employed previously
described SILAC-based technology11,30, using extracts
derived from CBFβ-MYH11-knockdown ME-1 cells
grown in light (L) or heavy (H)-labeled medium, incu-
bated with oligonucleotides containing the RUNX1 motif
(see Methods section). Of the >1300 identiﬁed proteins at
a high conﬁdence level, only a limited number displayed
highly signiﬁcant SILAC-ratios (>2) as CBFβ-MYH11
interactors. The CBFβ-MYH11 complex seems to facil-
itate the recruitment of MYH9 and MYL6 proteins to
RUNX1 sites, as shown by their enrichment in the pull-
down assay from ME-1 lysates (Fig. 5b). Interestingly,
upon CBFβ-MYH11 knockdown, two transcription fac-
tors (TFs), GATA2 and KLF1, are strongly enriched at
RUNX1 occupancy loci, implying that these might play a
crucial role in coordinating the RUNX1-dependent reg-
ulatory network in normal cells. Our previous ﬁndings
demonstrated that GATA2 and KLF1 displayed enhanced
levels in transcription after CBFβ-MYH11 knockdown11,
and the present work could conﬁrm not only increased
RNA expression, but also stronger binding to the RUNX1
containing oligo by western blot (Supplementary Figure
6A, B), suggesting that the two TFs are repressed and
might be replaced by CBFβ-MYH11 fusion in inv(16)
AML. These ﬁndings are further supported by our pre-
vious inability to detect GATA2 and KLF1 as binders of
RUNX1 sites11, as these assays were also done in the
presence of CBFβ-MYH11.
GATA2/CBFβ-MYH11 switching might drive
megakaryocyte/erythrocyte differentiation
As GATA2 is the highest expressed GATA factor in
ME-1 cells, we investigated the genome-wide binding
pattern by ChIP-seq in control and CBFβ-MYH11-
knockdown inv(16) cells, and also examined the RUNX1-
binding proﬁle in parallel. The genome-wide screen
indicated that GATA2 occupied similar genomic regions
as RUNX1 at most locations. Quantifying GATA2 occu-
pancy at RUNX1 loci revealed 2410 sites with increased
GATA2 signal and only 25 reduced binding sites. The
2410 regions showed increased RUNX1 occupancy but
reduced CBFβ-MYH11 binding (Fig. 6a), and associated
genes were involved in megakaryocyte/erythrocyte dif-
ferentiation and platelet formation. Furthermore, genes
associated with the 2410 regions were increased in
expression levels, which was further reﬂected by elevated
occupancy level of the H3K27ac mark (Fig. 6b, c), indi-
cating activation of the GATA2-target gene program after
the knockdown of CBFβ-MYH11. As could be expected,
motif discovery at these regions presented remarkable
enrichment for the GATA motif (Fig. 6d). In addition, also
overrepresentation for the EGR motif was detected, sug-
gesting that TFs binding this motif are potentially
involved in modulating the gene transcription process in a
synergistic manner (Fig. 6d).
To probe whether enforced GATA2 expression is suf-
ﬁcient to switch on this gene program, we transduced
ME-1 cells with a GATA2 expression construct and
performed global RNA-seq analysis. During hematopoi-
esis, overexpression of GATA2 shows a decrease in cell
proliferation and induces differentiation toward the
megakaryocyte lineage31. Here, global transcriptional
analysis identiﬁed a total of 367 genes increased and 171
genes decreased in transcriptional levels after GATA2
overexpression (Fig. 6e). As expected, these upregulated
genes contained GATA2 and several speciﬁc marker
genes linked to megakaryocytic/erythrocyte differentia-
tion, such as CD61, HBD, HBB, EGR1, and GATA1
(Fig. 6f), and were mainly associated with various signal-
ing pathways. Comparing transcriptomic changes after
GATA2 overexpression with those observed after CBFβ-
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MYH11 knockdown displayed moderate correlation (r=
0.559) based on relative expression ratio, and only showed
the overlap of 20 genes (5.4%) increased in expression and
19 genes (11.1%) decreased. These results suggest that
enforced GATA2 expression alone can partly reboot the
gene program involved in megakaryocyte-directed differ-
entiation, despite insufﬁciency to completely mimic
CBFβ-MYH11 knockdown.
Together, these ﬁndings suggest that activation of the
GATA2-involved regulatory program after CBFβ-MYH11
Fig. 6 Overexpression of GATA2 can partly induce a gene program involved in megakaryocyte-directed differentiation. a Associated
regulators and functional enrichment (ChIP-seq) in regions with increased GATA2 intensity after CBFβ-MYH11 knockdown (KD). b, c Genomic loci
with elevated GATA2 signal show higher expression levels (b) of associated genes and H3K27ac occupancy (c) in the CBFβ-MYH11-knockdown cells.
d Motif enrichment in regions with increased GATA2 density. e Gene changes upon GATA2 expression in ME-1 cells. (right) Enriched KEGG pathways
of differentially expressed genes after enforced GATA2 expression. f Upregulated cell marker genes induced by GATA2 overexpression. g Correlation
of deregulated genes between ME-1 cells overexpressing GATA2 and ME-1 cells upon CBFβ-MYH11 knockdown. Pearson correlation coefﬁcient and
p-value are shown
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knockdown is central but not sufﬁcient in driving further
differentiation, which is potentially orchestrated in colla-
boration with other factors like KLF1 and/or EGR1.
Discussion
The CBFβ-MYH11 fusion arising from inv(16) rear-
rangement was reported to lead to differentiation block-
age of normal myeloid cells and result in AML, but
whether this fusion blocks speciﬁc cell commitment has
not been discerned. Here, we compared the global land-
scapes of gene expression, DNA accessibility, and
H3K27ac between primary inv(16) AML blasts and nor-
mal cell types, and further investigated the functional
contributions of CBFβ-MYH11 and its involved reg-
ulatory program in vitro.
Comprehensive transcriptomic exploration in vivo not
only consolidated our previous ﬁndings11,12,32, but pin-
pointed towards unique gene expression programs
underlying inv(16) AML cells. Further epigenomic ana-
lyses indicated more shared epigenetic determiners
between inv(16) AML blasts and Mega/Ery cells, sug-
gesting that primary inv(16) AML cells might be epigen-
etically primed for Mega/Ery differentiation with some
key transcriptional pathways blocked. Therefore, in inv
(16) leukemogenesis, the CBFβ-MYH11 fusion might
skew leukemic blasts towards the Mega/Ery phenotype by
epigenetic predisposition33 or be involved in setting up a
speciﬁc Mega/Ery differentiation block by altering the
cells gene program.
We have shown previously that CBFβ-MYH11 could
activate transcription of self-renewal genes, and also
repress expression of differentiation markers in the con-
text of the cell line model ME-111. Here, we used in vitro
models with a single mutation (expression of CBFβ-
MYH11) for surveying the role of CBFβ-MYH11. Using
an iPSC system with dox-inducible CBFβ-MYH11
revealed that this fusion is able to speciﬁcally block
in vitro Mega/Ery differentiation, but hardly has any
effects on granulocyte and monocyte maturation. This
ﬁnding suggests expression of CBFβ-MYH11 affects spe-
ciﬁc cell differentiation pathways.
Previous studies have proposed that CBFβ-MYH11
impairs normal binding of other proteins due to the
higher afﬁnity with RUNX1, and alters expression of
RUNX1-dependent target gene sets11,12,34. We found that
GATA2 and KLF1 showed elevated expression levels11
and also acted as signiﬁcant interactors of RUNX1 after
CBFβ-MYH11 knockdown, suggesting that CBFβ-MYH11
alters normal transcriptional programs of the two reg-
ulators and competitively takes over their binding sites at
RUNX1 occupancy loci. GATA2 and KLF1 exert key
effects in the Mega/Ery lineage fate decision via interac-
tion with other modulators35–37. Our RNA-seq analysis
revealed attenuated expression levels of GATA2 and KLF1
in inv(16) blasts as compared to Mega/Ery, and that
GATA2 overexpression could partly reboot a
megakaryocyte-like gene program. As such, in line with
previous reports38, weak expression of GATA2 might be
essential for inv(16) leukemia, and responsible for partial
myelomonocytic differentiation featured by occasional
cells of “hybrid” nature (nuclear characteristics of
monocytes and both basophilic and eosinophilic gran-
ules), but increased GATA2 levels are needed for further
differentiation. Focusing on GATA2, ChIP-seq illumi-
nated its transcriptional activation role at these RUNX1-
dependent target genes by increased recruitment of his-
tone acetyltransferase activity and putative other TFs like
EGR1 (refs. 39–41). Consequently, the data suggest that the
GATA2-involved binding/regulatory program might be
obstructed by the CBFβ-MYH11 fusion, leading to block
of differentiation towards Mega/Ery in inv(16)
leukemogenesis.
Megakaryocyte and erythrocyte share plenty of com-
mon molecular signatures, but the two cell types also
exhibit distinct patterns in subtle regulatory networks35,42.
High transcription of GATA2 has been reported to solely
promote megakaryocyte differentiation and suppress
erythroid maturation43. In our study, GATA2 over-
expression boosted expression levels of some typical
marker genes driving Mega differentiation but did not
display a strong correlation with results from CBFβ-
MYH11 knockdown. This ﬁnding reveals that CBFβ-
MYH11 interferes with coordinated orchestration of a
precise balance of multiple factors in maturing Mega/Ery,
but the enforced expression of GATA2 only recapitulates
megakaryocyte differentiation during bifurcation of the
two lineages. As a consequence, GATA2 alone is not
sufﬁcient to inhibit CBFβ-MYH11-caused leukemia, and
it maybe has greater functional relevance only in context
with overexpression of other regulators like KLF1.
In summary, our study suggests that the CBFβ-MYH11
fusion maintains inv(16) AML cells by attenuating
expression levels of GATA2 and blocks their further dif-
ferentiation towards Mega/Ery lineages via interfering
with a GATA2/KLF1-involved regulatory network. Col-
lectively, these results corroborate our previous ﬁndings,
facilitate a better molecular understanding of the role of
CBFβ-MYH11 in the pathogenesis of leukemia, and might
ultimately help to improve therapy decision of inv(16)
AML by designing speciﬁc (epi)drugs to reprogram
GATA2 or other target genes.
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